Results (3750)
Positive opinion for extension of indication from age of six
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting

Doxycycline: currently available evidence not supporting link with risk of suicidality

Marketing authorisation holders can now use the platform to report shortages of centrally authorised human medicines.
EMA is advising marketing authorisation holders to submit type I variations for 2024 no later than 30 November 2024.
Use of opioid medicines with Mysimba may lead to serious side effects

Leqembi (lecanemab) recommended for treatment of early Alzheimer’s disease
Regulatory update

Re-examination concludes that benefits outweigh risks in a restricted patient population

Platform technologies enable rapid response to emerging infectious disease threats